U.S. Court of Appeals Denies Appeal in Baraclude Patent Case
2014-06-12 · Bristol-Myers Squibb · original bms.com ↗
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Court of Appeals for the Federal Circuit has denied the company’s appeal of a February 2013 ruling by the U.S. District Court for the District of Delaware that found the patent covering Baraclude (entecavir), U.S. patent 5,206,244 invalid. The company is reviewing the decision and considering all its legal options. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews . Bristol-Myers SquibbMediaFrederick Egenolf, [email protected] RelationsRyan Asay, [email protected] Dajani, [email protected]
The release as fetched from its publisher. bms.com ↗